In addition, more CAR-T therapies targeting other cancers are under preclinical and clinical studies, such as mesothelin-targeting CAR-T cells to treat ovarian cancer, and CD70-targeting CAR-T cells to treat acute myeloid leukemia (AML) [20,21]. This evidence concerns the gene MSLN and cancer.